ArticleNPJ precision oncology2026
Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antibody-Drug Conjugates Targeting HER2 and Trop-2: A New Force in Precision Treatment for Solid Tumors.Pharmaceuticals (Basel, Switzerland) · 2026Review
- TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Trop2-directed antibody-drug conjugates (ADCs) show activity across epithelial cancers, yet determinants of target expression in tumors and normal tissues remain poorly defined. We integrated bulk and single-cell transcriptomic profiles from over 20,000 samples across TCGA, GTEx and public atlases to map TACSTD2 expression, regulation and functional correlates in solid malignancies and healthy epithelia. TACSTD2 was restricted to epithelial lineages, enriched in multiple tumors and detectable in selected normal epithelia. Genomic alterations were uncommon, whereas DNA methylation showed a consistent inverse association with expression, indicating dominant epigenetic control. TACSTD2 expression was linked to epithelial programs shaping the tumor microenvironment, including pathways related to barrier integrity and variable immune interactions across tumor types, with potential implications for combination with immune-checkpoint inhibitors. Across histologies, TACSTD2 showed modest and context-dependent co-expression with genes involved in ADC-processing and payload sensitivity. These findings indicate that antigen abundance alone is insufficient to predict ADC efficacy or toxicity across histologies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.